S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The gold catalyst we’ve waited for (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
The gold catalyst we’ve waited for (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The gold catalyst we’ve waited for (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
The gold catalyst we’ve waited for (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The gold catalyst we’ve waited for (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
The gold catalyst we’ve waited for (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Biden To Unleash "Choke Point" Operation On America? (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The gold catalyst we’ve waited for (Ad)
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
The gold catalyst we’ve waited for (Ad)
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
OTCMKTS:HKMPF

Hikma Pharmaceuticals - HKMPF Stock Forecast, Price & News

$20.64
0.00 (0.00%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$20.64
$20.64
50-Day Range
$18.87
$21.36
52-Week Range
$13.76
$28.00
Volume
N/A
Average Volume
205 shs
Market Capitalization
$4.55 billion
P/E Ratio
N/A
Dividend Yield
3.59%
Price Target
N/A

HKMPF stock logo

About Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Receive HKMPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HKMPF Stock News Headlines

"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Hikma Pharmaceutical FY EPS 83.6c
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
HKMPF Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC HKMPF Stock Chart
Hikma Pharma slides on lower generics guidance
Hikma Pharmaceuticals Plc 1H Rev $1.21B
Hikma Pharma CEO Siggi Olafsson Resigns - Quick Facts
See More Headlines
Receive HKMPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HKMPF Company Calendar

Today
3/26/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HKMPF
CIK
N/A
Employees
8,700
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.52 billion
Cash Flow
$2.41 per share
Book Value
$10.18 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.55 billion
Optionable
Not Optionable
Beta
0.53

Key Executives

  • Said Samih Taleb Darwazah
    Executive Chairman & Chief Executive Officer
  • Khalid Walid Hosni Nabilsi
    Chief Financial Officer
  • Mazen Samih Taleb Darwazah
    Executive Vice Chairman & President-MENA Region
  • Majda Labadi
    Executive VP-Organizational Development
  • Riad Mishlawi
    President-Injectables Division













HKMPF Stock - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HKMPF shares.
View HKMPF analyst ratings
or view top-rated stocks.

How have HKMPF shares performed in 2023?

Hikma Pharmaceuticals' stock was trading at $18.87 at the beginning of 2023. Since then, HKMPF stock has increased by 9.4% and is now trading at $20.6401.
View the best growth stocks for 2023 here
.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (OTCMKTS:HKMPF) pays an annual dividend of $0.74 per share and currently has a dividend yield of 3.59%.
Read our dividend analysis for HKMPF.

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $20.64.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals (OTCMKTS:HKMPF) has a market capitalization of $4.55 billion and generates $2.52 billion in revenue each year.

How many employees does Hikma Pharmaceuticals have?

The company employs 8,700 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The official website for the company is www.hikma.com. The company can be reached via phone at 442073992760, via email at investors@hikma.uk.com, or via fax at 44-20-7399-2761.

This page (OTCMKTS:HKMPF) was last updated on 3/26/2023 by MarketBeat.com Staff